Squarepoint
LENZ

Squarepoint’s LENZ Therapeutics LENZ Stock Holding History

Squarepoint’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.92M Buy
1,747,096
+240,597
+16% +$1.94M 0.01% 1106
2026
Q1 		$13.8M Buy
1,506,499
+1,014,601
+206% +$14.3M 0.02% 905
2025
Q4 		$7.87M Buy
491,898
+402,110
+448% +$11.7M 0.01% 1196
2025
Q3 		$4.18M Buy
89,788
+79,815
+800% +$2.93M ﹤0.01% 1571
2025
Q2 		$292K Sell
9,973
-17,962
-64% -$489K ﹤0.01% 3712
2025
Q1 		$718K Buy
+27,935
New +$688K ﹤0.01% 2953
2024
Q4 		– Sell
-12,654
Closed -$300K – 5578
2024
Q3 		$300K Buy
12,654
+2,177
+21% +$48.3K ﹤0.01% 3444
2024
Q2 		$181K Buy
+10,477
New +$183K ﹤0.01% 3685
2024
Q1 		– Sell
-1,767
Closed -$32.4K – 4709
2023
Q4 		$32.4K Buy
+1,767
New +$29.2K ﹤0.01% 3884
2023
Q2 		– Sell
-2,016
Closed -$34.6K – 4097
2023
Q1 		$34.6K Buy
+2,016
New +$32.6K ﹤0.01% 3087
2022
Q3 		– Sell
-1,678
Closed -$32K – 3527
2022
Q2 		$32K Buy
+1,678
New +$37.4K ﹤0.01% 2749
2021
Q3 		– Sell
-5,714
Closed -$1.23M – 3515
2021
Q2 		$1.23M Buy
+5,714
New +$995K ﹤0.01% 1486

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Squarepoint's LENZ Position: Q2 2026 in Review

Squarepoint increased its LENZ Therapeutics (LENZ) stake by 16% in Q2 2026, buying an estimated $1.94M and bringing the position to 1,747,096 shares worth $9.92M. The position accounts for 0.01% of the portfolio, ranked #1106.

Squarepoint first reported a position in LENZ in Q2 2021 and has held it in 12 quarters since. The position peaked at $13.8M in Q1 2026. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Squarepoint held 1,747,096 shares of LENZ Therapeutics worth $9.92M as of Q2 2026.
  • Squarepoint bought 240,597 LENZ Therapeutics shares in Q2 2026, an estimated $1.94M.
  • LENZ Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1106 holding.
  • Squarepoint first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • Squarepoint's LENZ Therapeutics position peaked at $13.8M in Q1 2026.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.